DDW: Lilly’s Omvoh shows four-year UC clearance

In the Phase III trial, 63.5% of patients treated with Lilly's Omvoh remained disease free after four years. In the Phase III trial, 63.5% of patients remained disease free after four years. Lilly said this is the first time four year disease clearance has been reported with a drug of this class. Credit: Michael Vi / Shutterstock.com Eli Lilly’s Omvoh (mirikizumab-mrkz) has shown four-year disease-clearance in patients with moderately to severely active ulcerative colitis (UC). In the LUCENT-3 (NCT03519945) open-label extension study, 63.5% of Omvoh-treated patients who achieved disease clearance at one year sustained it at four years. Even in…

Source: Clinical Trials Arena